Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fulgent GeneticsFRA:7F0 67 Debt-to-EBITDA is -0.11 as of Jun. 2026. GuruFocus rates FRA:7F0 with a GF Score™ of 67/100 and a GF Value™ of €20.77 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 877192.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Fulgent Genetics's Debt-to-EBITDA or its related term are showing as below:
FRA:7F0'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.17 Med: 0.03 Max: 1.59
Current: -0.14
During the past 12 years, the highest Debt-to-EBITDA Ratio of Fulgent Genetics was 1.59. The lowest was -0.17. And the median was 0.03.
FRA:7F0's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.305
vs FRA:7F0: -0.14
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Fulgent Genetics Debt-to-EBITDA Related Terms
Fulgent Genetics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7F0 vs MYGN, CSTL, BDSX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Fulgent Genetics (FRA:7F0) has a Debt-to-EBITDA of -0.11 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Fulgent Genetics. According to the industry distribution chart, Fulgent Genetics ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is Fulgent Genetics' Debt-to-EBITDA too high?
Fulgent Genetics' current Debt-to-EBITDA is -0.11. Based on the distribution chart, Fulgent Genetics ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Fulgent Genetics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Debt-to-EBITDA compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #999999 out of 114 companies for Debt-to-EBITDA. This places Fulgent Genetics in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Fulgent Genetics. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current Debt-to-EBITDA is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FRA:7F0) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.77, compared to a current price of €16.00 — trading 23% below its estimated fair value. The current Debt-to-EBITDA is -0.11. Fulgent Genetics' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Fulgent Genetics (FRA:7F0), the current Debt-to-EBITDA is -0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FRA:7F0) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of €16.00 is trading 23% below its estimated GF Value™ of €20.77.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FRA:7F0:
Debt-to-EBITDA: -0.11
GF Value™: €20.77 vs. price of €16.00 (23% below fair value)
No single metric tells the full story. See the FRA:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
67GF Score
Get the complete analysis for FRA:7F0
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7F0 has been successfully added to your 
